FGEN - FibroGen Inc Net earnings per share (EPS TTM)
Following a series of trial failures, FibroGen, Inc. (FGEN) underwent a restructuring, reducing headcount to minimize base expenses. The 12-month EPS trend clearly demonstrates the results of this optimization, where the value 40.37 represents the current yield. Recruiting top biologists ensures the development of unique drugs, while the use of external CDMO plants in California completely mitigates the risks of proprietary equipment downtime.
Comprehensive metric breakdowns and analytics for FibroGen Inc (FGEN)
- share price and expert price forecast:
- market capitalization statistics:
- business book valuation details:
- debt obligations and liquidity statistics:
- net income and valuation multiples indicators:
FGEN - Company Net Income|Projected Future Earnings FibroGen, Inc.|FGEN - Market Cap to Net Income Ratio|Forward P/E Multiple FibroGen|FGEN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen, Inc.|FGEN - Operating profit before amortization|Net earnings per share for the last 12 months FibroGen|FGEN - Earnings per share for the trailing year|Quarterly EPS earnings growth fibrogen.com|FGEN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year FibroGen, Inc.
Fundamental company analysis:FibroGen, Inc. (FGEN)
Net income per share (TTM) consolidates annual earnings, excluding quarterly volatility to assess real capital efficiency. This metric determines the portion of profit attributable to a single share in real-time. By analyzing the change in per-share profit over the last 12 months, an investor can see the financial outcome of FibroGen, Inc. (FGEN) competing with pharma behemoths. For this inhibitor developer, this figure reflects the monetization of clinical successes. EPS dynamics serve as an indicator of business resilience in the face of fierce patent competition.
Competitor analysis for FibroGen, Inc.
HLN: Net earnings per share for the last 12 months|kenvue.com - Earnings per share for the last four quarters|VRNA: Net earnings per share (EPS TTM)|Jyong Biotech Limited - Earnings per share for the trailing year|LGND (Ligand Pharma) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Amneal Corp AMRX|Earnings per share for the last twelve months Perrigo Company plc (PRGO)|ALVO (alvotech.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) LQDA (Liquidia)|GLPG (Galapagos N.V.) - Earnings per one share for the last 12 months|ANI Pharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Afrezza MNKD|AMPH: Net earnings per share (EPS TTM)|PCRX (pacira.com) - Earnings per share for the last twelve months|Earnings per share for the last twelve months ARS Pharmaceuticals, Inc.|TBPH: Earnings per share for the trailing year|Earnings per share for the last twelve months Aquestive Pharma (AQST)|SCPH - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) TECX (Tectonic Therapeutic)|Net earnings per share for the trailing year tonixpharma.com|SXT China - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Eupraxia Pharmaceuticals|BioHarvest (BHST) - Earnings per share for the last twelve months|Earnings per share for the last 12 months EXOZ|Net earnings per share for the last 12 months ORMP|ENTX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) HYFT|Net earnings per share for the last four quarters ABVC BioPharma Inc.|Earnings per share for the last twelve months Cumberland Pharma CPIX|QNTM: Earnings per share for the last 12 months|Telomir Pharmaceuticals - Net earnings per share (EPS TTM)|Rani Therapeutics (RANI) - Net earnings per share for the last 12 months|SNYR (synergychc.com) - Net earnings per share for the last 12 months|RLYB - Net earnings per share for the last four quarters|LEXX (Lexaria Bioscience Corp) - Net earnings per share (EPS TTM)|Pulmatrix Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PTHL|aptorumgroup.com (APM) - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) LYRA (Lyra Therapeutics)|Impact BioMedical, Inc. (IBO) - Net earnings per one share for the last twelve months|TNFA - Earnings per share for the last twelve months|YCBD (cbdMD, Inc.) - Earnings per share for the last 12 months|PainReform Ltd. (PRFX) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months CYTO (Altamira Therapeutics Ltd.)|LIPO (Lipella Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|OPTN: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PIRS|Net earnings per share (EPS TTM) Procaps Group Corp (PROC)|Earnings per share for the last twelve months Petros Pharmaceuticals PTPI|Earnings per share for the trailing year QLI|SLRN - Earnings per share for the last twelve months|TFF Pharmaceuticals Inc. (TFFP) - Net earnings per share for the last 12 months
